How our Unique Anti-Infectives Targets Bacterial and Viral Infections
Since 1987, no new class of human antibiotics have come on to the market. Our new class of antibiotic has been synthesised using a unique and economic method of manufacture. Unlike current antibiotics, which rely on a specific ‘lock and key fit’ between the antibiotic and the bacteria causing the disease, our antibiotics have been designed to overcome this shortfall, starting at the process of our patented antibiotic synthesis.
RECCE® 327 may be administered for intravenous, topical, nasal, oral and inhaled use. RECCE® 327’s universal mechanism of action has a patented ability to continuously kill bacteria without tendency for the emergence of resistance, even with repeated use, indicating a unique ability to combat antibiotic resistant superbugs.
Before application of RECCE® 327,
the E.coli bacteria cells are healthy,
smooth and intact.
Atter application of RECCE® 327 ,
the E.coli bacteria cell membrane
begins to weaken and is disrupted
E.coli bacteria cells (10e6 cfu/ml) having their outer membrane weakened and bursting from treatment with RECCE® 327 (1000 ppm)
Electron microscope images generated by Dr Peta Clode and Lyn Kirilak of the Centre for Microscopy, Characterisation and Analysis, University of Western Australia, demonstrate RECCE® 327’s unique mechanism of action.
Studies to date indicate RECCE® 327 to have a unique ability to cause bacterial cell lysis without undue inhibition of healthy cells.
Data indicates RECCE® 327’s mechanism of action to work through:
- Hydrophobic interactions with the polymer non-specifically attract and bind the antibiotic to proteins of the bacterial plasma membrane.
- Subsequent disruption of the bacterial cell wall and the high internal pressure in bacteria (up to 10 atmospheres) leads to cell lysis.
- Non-bacterial (eukaryotic) cells remain intact since they do not contain high internal pressures to result in cell lysis.
RECCE® 529 is a new synthetic polymer formulation with indication against viruses. The Company looks forward to expanding upon this promising indication in due course.
The Company continues to strengthen and expand their product pipeline in order to find a treatment for ‘difficult to treat’ viral infections.